Unicycive Therapeutics Inc

CUSIP 90466Y202COM NEWUNCYQ1 2026

13D / 13G Filings

Schedule 13D/13G on record

Beneficial Filers

Distinct reporting persons

Largest Stake

11.0%

Max % of class reported

Institutional Holders

13F filers (latest quarter)

11 filings · latest Feb 17, 2026

#	Filed	Reporting Person	Form	% of Class	Shares	Filing
1	Feb 17, 2026	Ra Capital Management, L.P.	13G/A	9.9%	2.39M	SEC
2	Feb 13, 2026	Nantahala Capital Management, LLC	13G/A	10.0%	2.28M	SEC
3	Feb 10, 2026	Octagon Capital Advisors LP	13G/A	4.7%	1.00M	SEC
4	Jan 23, 2026	Integrated Core Strategies (Us) LLC	13G	11.0%	1.17M	SEC
5	Nov 14, 2025	Great Point Partners, LLC	13G/A	4.5%	796.6K	SEC
6	Nov 14, 2025	Ra Capital Management, L.P.	13G/A	9.9%	1.96M	SEC
7	Nov 14, 2025	Octagon Capital Advisors LP	13G/A	5.7%	1.00M	SEC
8	Nov 14, 2025	Vivo Opportunity Fund Holdings, L.P.	13G/A	10.0%	6.10M	SEC
9	Aug 14, 2025	Great Point Partners, LLC	13G/A	6.2%	796.6K	SEC
10	Aug 14, 2025	Biotechnology Value Fund L P	13G/A	10.0%	1.42M	SEC

See the full Schedule 13D/13G history for Unicycive Therapeutics Inc.

Largest reported positions · latest quarter

#	Fund	Shares	Value
1	Vivo Capital, LLC	1.79M	$11.78M
2	Millennium Management LLC	1.40M	$9.21M
3	Octagon Capital Advisors LP	1.00M	$6.58M
4	Nantahala Capital Management, LLC	939.2K	$6.18M
5	Great Point Partners LLC	796.6K	$5.24M
6	Logos Global Management LP	473.6K	$3.12M
7	Citadel Advisors LLC	236.8K	$1.56M
8	Integral Health Asset Management, LLC	225.0K	$1.48M
9	Geode Capital Management, LLC	203.7K	$1.34M
10	Susquehanna International Group, LLP	199.2K	$1.31M